AZ\'s Tagrisso secures China approval in firstline advanced lung cancer

AZ's Tagrisso secures China approval in first-line advanced lung cancer

AstraZeneca’s Tagrisso (osimertinib) has secured approval in China from the country’s National Medical Products Administration (NMPA) in the first-line treatment of locally-advanced or metastatic non-small cell lung cancer (NSCLC), it has emerged.

The authorisation, achieved via the Priority Review Pathway, covers adult patients whose tumours have the genetic mutations of epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitutions.

read more

Original Article: AZ's Tagrisso secures China approval in first-line advanced lung cancer

More From BioPortfolio on "AZ's Tagrisso secures China approval in first-line advanced lung cancer"